GYRE (Gyre Therapeutics) Non Operating Income: $-5.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GYRE Gyre Therapeutics Inc GYRE
43 GF Score
Price $6.84
GF Value $9.41
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Gyre Therapeutics Non Operating Income?

Gyre Therapeutics GYRE +6.52% 43 Non Operating Income is $-5.0 Mil as of Jun. 2026. GuruFocus rates GYRE with a GF Score™ of 43/100 and a GF Value™ of $9.41 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Gyre Therapeutics's Non Operating Income for the three months ended in Jun. 2026 was $-1.3 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was $-5.0 Mil.

Gyre Therapeutics Non Operating Income Related Terms

Gyre Therapeutics Non Operating Income Historical Data

* Premium members only.

The historical data trend for Gyre Therapeutics's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gyre Therapeutics Non Operating Income Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
-0.79 -0.52 -97.22 5.44 1.20

Gyre Therapeutics Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.28 0.70 -1.93 -2.44 -1.31
GYRE
43GF Score
Gyre Therapeutics Inc GYRE
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gyre Therapeutics Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $-5.0 Mil mean?
Gyre Therapeutics (GYRE) has a Non Operating Income of $-5.0 Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Gyre Therapeutics and its competitors.
Is Gyre Therapeutics' Non Operating Income too high?
Gyre Therapeutics' current Non Operating Income is $-5.0 Mil. Overall, Gyre Therapeutics has a GF Score™ of 43/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' Non Operating Income compare to CTMX and BBOT?
Gyre Therapeutics' Non Operating Income of $-5.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Gyre Therapeutics and its competitors. Gyre Therapeutics's current Non Operating Income is $-5.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Gyre Therapeutics (GYRE) is currently considered Modestly Undervalued. The stock's GF Value™ is $9.41, compared to a current price of $6.84 — trading 27.3% below its estimated fair value. The current Non Operating Income is $-5.0 Mil. Gyre Therapeutics' overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Gyre Therapeutics (GYRE), the current Non Operating Income is $-5.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gyre Therapeutics (GYRE) Overvalued in 2026?

Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued. The current stock price of $6.84 is trading 27.3% below its estimated GF Value™ of $9.41. GuruFocus considers Gyre Therapeutics to be Modestly Undervalued.

Key valuation signals for GYRE:

  • Non Operating Income: $-5.0 Mil
  • GF Value™: $9.41 vs. price of $6.84 (27.3% below fair value)
  • GF Score™: 43/100 with 3 warning signs

No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gyre Therapeutics Business Description

Other Exchanges L9S:Germany
Address 12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
43GF Score

Get the complete analysis for GYRE

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.84
Price
$9.41
GF Value